PhI­II set­back mars Oc­u­lar's glau­co­ma drug/de­vice, though com­pa­ny re­mains 'en­cour­aged' by da­ta break­down

Oc­u­lar Ther­a­peu­tix’s lat­est drug/de­vice — for glau­co­ma — has flopped in its Phase III study, fail­ing the pri­ma­ry end­point to sig­nif­i­cant­ly re­duce in­traoc­u­lar pres­sure ver­sus place­bo.

The treat­ment, OTX-TP, is an in­tra­canalic­u­lar in­sert de­signed to de­liv­er a for­mu­la­tion of the drug travo­prost with an ef­fect up to 90 days, which Oc­u­lar says can solve the ad­her­ence is­sues seen with dai­ly eye drop reg­i­mens that pa­tients are typ­i­cal­ly pre­scribed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER